The smartHEALTH European Digital Innovation Hub experiences and challenges for accelerating the transformation of public and private organizations within the innovation ecosystem.

Digital innovation can significantly enhance public health services, environmental sustainability, and social welfare. To this end, the European Digital Innovation Hub (EDIH) initiative was funded by the European Commission and national governments aiming to facilitate the digital transformation on various domains (including health) via the setup of relevant ecosystems consisting of academic institutions, research centres, start-ups, small and medium-sized enterprises, larger companies, public organizations, technology transfer offices, innovation clusters, and financial institutions. The ongoing goal of the EDIHs initiative is to bridge the gap between high-tech research taking place in universities and research centres and its deployment in real-world conditions by fostering innovation ecosystems.

Sketching the vision of the Web of Debates.

The exchange of comments, opinions, and arguments in blogs, forums, social media, wikis, and review websites has transformed the Web into a modern agora, a virtual place where all types of debates take place. This wealth of information remains mostly unexploited: due to its textual form, such information is difficult to automatically process and analyse in order to validate, evaluate, compare, combine with other types of information and make it actionable. Recent research in Machine Learning, Natural Language Processing, and Computational Argumentation has provided some solutions, which still cannot fully capture important aspects of online debates, such as various forms of unsound reasoning, arguments that do not follow a standard structure, information that is not explicitly expressed, and non-logical argumentation methods.

Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group.

Background: The long-term outcome of rheumatoid arthritis (RA) patients who in clinical practice exhibit persistent moderate disease activity (pMDA) despite treatment with biologics has not been adequately studied. Herein, we analyzed the 5-year outcome of the pMDA group and assessed for within-group heterogeneity.

Methods: We included longitudinally monitored RA patients from the Hellenic Registry of Biologic Therapies with persistent (cumulative time ≥ 50% of a 5-year period) moderate (pMDA, 3.